Abstract: An electroluminescent element is disclosed, comprising an electroluminescent material and a fluorescent substance emitting light having an emission maximum at the wavelength different from that of light emitted from the electroluminescent material upon absorption of the light emitted from the electroluminescent material. A color conversion filter is also disclosed, comprising a fluorescent substance emitting light having an emission maximum at the wavelengths of 400 to 700 nm upon absorption of the light emitted from the electroluminescent material.

Abstract: Thiacrown polymers immobilized to a polystyrene-divinylbenzene matrix react with Hg2+ under a variety of conditions to efficiently and selectively remove Hg2+ ions from acidic aqueous solutions, even in the presence of a variety of other metal ions. The mercury can be recovered and the polymer regenerated. This mercury removal method has utility in the treatment of industrial wastewater, where a selective and cost-effective removal process is required.

Abstract: Describes novel polyfunctional thiiranes. Also described are polymerizable compositions comprising such novel polyfunctional thiiranes, and polymerizates, e.g., optical lenses, prepared therefrom. The described polymerizates may have a refractive index of at least 1.6, and an Abbe number of at least 27.

Abstract: The p-aminophenol derivative compounds of formula (I), or their physiologically compatible water-soluble salts: are useful as developer compounds in oxidation dye compositions for keratin fibers. Oxidation dye compositions for keratin fibers, including hair, and methods of dyeing hair using the p-aminophenol derivative compounds are also described.

Abstract: This invention relates to thermosetting resin compositions useful for mounting onto a circuit board semiconductor devices, such as CSPs, BGAs, LGAs and the like, each of which having a semiconductor chip, such as LSI, on a carrier substrate. The compositions of this invention are reworkable when subjected to appropriate conditions.

Abstract: The present invention relates to a compound of formula (I): 1

Abstract: The present invention is directed to electro-optico chromophore bridge compounds and donor-bridge compounds which can be used in the preparation of polymeric thin films for waveguide media.

Abstract: The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.

Abstract: A sulfonic acid compound of a cyclic phenol sulfide represented by formula (1): (wherein X represents a hydrogen atom, a hydrocarbon group, or an acyl group; M represents a hydrogen atom, an alkyl group, a metal, ammonium, (lower-alkyl)ammonium, (lower-alkanol)ammonium, a nitrogen-containing heterocyclic group, or an amino acid residue; Z represents Sm, SO, or SO2; m is an integer of from 1 to 7; and n is an integer of from 4 to 12, with the proviso that the plural X's, M's and Z's are each the same or different, and at least one of the plural M's is neither a hydrogen atom nor an alkyl group), or a salt thereof; a composition for separating and recovering an organic halogen compound or a monocyclic aromatic compound, comprising a cyclic phenol sulfide or a salt thereof, and a carrier; and a pharmaceutical composition a cyclic phenol sulfide or a pharmaceutically acceptable salt, and a carrier.

Abstract: Provided is a new molecular compound excellent in luminous property, which has a molecular structure wherein a thiophene ring and a benzene (or naphthalene) ring are directly bonded to each other, as a molecular compound making it possible to control its luminous color relatively easily and realize highly efficient and bright luminescence. In this compound, its color tone of emitted light can be variously changed by altering the number of the thiophene ring and the benzene (or naphthalene) ring and the bonding order of the rings. Thus, if this molecular compound is used as a luminous material, it is possible to easily cope with both control of its luminous color and realization of highly efficient and bright luminescence. Use of a luminous material using this molecular compound makes it possible to realize luminescence having wide colors from violet to red highly efficiently.

Abstract: A composition and method for the catalytic conversion of a racemic mixture of dienes to a cyclic olefin by a ring-closing metathesis (RCM) reaction are disclosed. The composition, a transition metal complex with an M═C reaction site, contains a bidentate dialkoxide of at least 80% optical purity. Because the M═C reaction site is of a sufficient shape specificity, conferred in part by the dialkoxide of sufficient rigidity and a M═N—R1 site, reacting the composition with a mixture of two enantiomeric dienes results in an olefin metathesis product that has at least a 50% enantiomeric excess of one enantiomer in the mixture. A method is also provided for reacting a composition with a racemic diene mixture to generate a metathesis product that has an enantiomeric excess of at least 50%. Methods are also provided for catalytic enantioselective desymmetrization.

Abstract: The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.

Abstract: Thiacrown ether and polymeric thiacrown ether compounds are disclosed. The thiacrown ether ring structures are substituted and have from 4 to about 10 sulfur atoms on each of the crown rings. The polymeric thiacrown ether ring structures are substituted with polymers and have from 4 to about 10 sulfur atoms on each of the crown rings. The thiacrown compounds of the present invention are expected to have utility in a wide range of applications including but not limited to utility as metal ion chelating, sequestering, and complexing agents. The thiacrown compounds are also expected to have utility as corrosion inhibitors for cooling tower, boiler, and waste water systems, hydrocarbon process systems and metal surface treatments systems.

Abstract: A solid phase method for the synthesis of a plurality of differently substituted thiophenes with a wide variety of side-chain substituents as compounds of potential therapeutic interest is disclosed. The thiophenes are prepared by acylation of a substrate-bound primary or secondary amine with cyanoacetic acid and reaction of the resulting cyanoacetamide with an isothiocyanate in the presence of a base. Alkylation with an appropriate alkyl halide, followed by Thorpe-Ziegier-cyclization yields differently substituted, support-bound 3-aminothiophenes. These may be screened on the substrate or cleaved from the substrate and then screened in solution. Alternatively, the resin-bound 3-amino thiophenes or the synthetic intermediates can be subjected to further synthetic transformations (N-acylation, reduction) on the support, which permits the preparation of further therapeutically interesting compounds.

Abstract: The invention provides chemistry libraries containing fused 2,4-pyrimidinediones. The invention also provides methods for the construction of fused 2,4-pyrimidinedione containing libraries. The invention further provides methods for the identification of bioactive, fused 2,4-pyrimidinediones from those libraries.

Abstract: Fluorescent conjugates suitable for use in flow cytometry and other biological applications. The fluorescent conjugates comprise an antibody having a polymeric dye bound thereto. The polymeric dye is preferably enhanced by a hydrophobic and conformationally restrictive moiety either bound thereto or in close association therewith. The hydrophobic and conformationally restrictive moiety is preferably derived from a cyclodextrin. The polymeric dye comprises a polymeric entity having signal-generating groups, such as aminostyryl pyridinium dye residues attached thereto. The fluorescent conjugates exhibit exceptional stability characteristics and avoid many of the problems of energy transfer, bio-conjugability, and solubility.

Abstract: The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.

Abstract: This invention relates to a novel solid phase process for the preparation of thiophene combinatorial libraries. These libraries have use for drug discovery and are used to form wellplate components of novel assay kits.

Abstract: The present invention relates to a process for stereoselective or regioselective chemical synthesis which generally comprises reacting a nucleophile and a chiral or prochiral cyclic substrate in the presence of a non-racemic chiral catalyst to produce a stereoisomerically or regioselectively enriched product.

Abstract: Novel ligands for use in MRI contrast agents and which have the formula ##STR1## wherein R.sub.1 -R.sub.14, M", l, m, and n are defined herein.

Abstract: This invention provides a novel compound for .sup.35 S-labelling oligonucleotides. The compound is .sup.35 S-3H-1,2-benzodithiol-3-one-1,1 dioxide (1) ##STR1## wherein the asterisk indicates the position of the .sup.35 S. Also provided is a method of synthesizing this compound, comprising first contacting .sup.35 S-thiobenzoic acid (4) with thiosalicylic acid (5) in acid medium to yield the condensation product, .sup.35 S-3 H 1,2-benzodithiol-3-one (2). .sup.35 S-3 H 1,2-benzodithiol-3-one (2) is then oxidized with a suitable oxidating agent such as trifuoroacetic acid and hydrogen perioxide to yield the desired product, .sup.35 S-3H-1,2-benzodithiol-3-one-1,1 dioxide (1). Any oligonucleotide susceptible to oxidative sulfurized by 3H-1,2-benzodithiol-3-one-1,1 dioxide can be labeled by .sup.35 S-3H-1,2-benzodithiol-3-one-1,1 dioxide (1). Accordingly, this invention also provides novel methods for .sup.35 S-labelling oligonucleotides.

Abstract: A cyclic phenol sulfide represented by the following formula (1) is described: ##STR1## wherein X represents a hydrogen atom, a hydrocarbon group, or an acyl group; Y.sub.1 represents a hydrogen atom, a hydrocarbon group, a halogenated hydrocarbon group, --COR.sup.1, --OR.sup.2, --COOR.sup.3, --CN, --CONH.sub.2, --NO.sub.2, --NR.sup.4 R.sup.5, a halogen atom, --SO.sub.4 R.sup.6, or --SO.sub.3 R.sup.7, in which R.sup.11, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 each represents a hydrogen atom or a hydrocarbon group; n is an integer of 3 or more; and m is an integer of 1 to 7, provided that the plural m's of the S.sub.m 's are the same or different; the plural X's are the same or different; and the plural Y.sub.1 's are the same or different. A process for producing the cyclic phenol sulfide is also described.

Abstract: A process for the preparation of mixed crystals of 1,4-diketopyrrolo?3,4-c!pyrroles, consisting of 1 mol each of two different compounds of formula ##STR1## by heating a corresponding mixture in solid form to the temperature range from 220.degree. to 380.degree. C.A and B are, for example, each a group of formula ##STR2## wherein R.sub.1 and R.sub.2 are each independently hydrogen, chloro, bromo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkylamino, phenyl or --CN,G is --O--, --NR.sub.7 --, --N.dbd.N-- or --SO.sub.2 --,R.sub.3 and R.sub.4 are hydrogen, and R.sub.7 is hydrogen, methyl or ethyl.The mixed crystals and solid solutions obtained are excellently suited for pigmenting high molecular weight material.

Abstract: A process for producing an alkylene sulfide, which comprises the step of subjecting a mercaptoalkanol to an intramolecular dehydration reaction in the presence of an acidic dehydration catalyst, to produce the alkylene sulfide, in which the intramolecular dehydration reaction is conducted under at least one conditions of (1) to (3). (1) The intramolecular dehydration reaction is conducted in at least one solvent selected from the group consisting of compounds having an amide group N-substituted with a hydrocarbon group having from 1 to 6 carbon atoms, compounds having an unsubstituted amide group, compounds having a ureylene group N-substituted with a hydrocarbon group having from 1 to 6 carbon atoms, and compounds having an unsubstituted ureylene group. (2) The intramolecular dehydration reaction is conducted in a solvent under such temperature and pressure conditions that the reaction temperature T (.degree.C.) and the boiling point tb (.degree.C.

Abstract: DC107 derivatives represented by the formula (I): ##STR1## or pharmacologically acceptable slats thereof, ?wherein R.sup.1 is hydrogen, lower alkoxyalkyl, aralkyloxyalkyl, lower alkoxyalkoxyalkyl, lower alkoxyalkoxyalkoxyalkyl, aralkyl, tetrahydropyranyl, COR.sup.4 or the like; R.sup.2 represents hydrogen or COR.sup.5 ; R.sup.3 represents lower alkyl, lower alkenyl, aralkyl which may be substituted with substituted or unsubstituted aryl, lower alkoxyalkyl, aralkyloxyalkyl, substituted or unsubstituted aryloxyalkyl, lower alkoxycarbonylalkyl, lower alkanoyloxyalkyl, alicyclic alkanoyloxyalkyl or the like, or bonds to Y to represent a single bond; Y bonds to R.sup.3 to represent a single bond, or bonds to Z to represent a single bond; Z represents hydrogen or bonds to Y to represent a single bond; W represents oxygen or NR.sup.6, with the proviso that the compound wherein R.sup.1, R.sup.2 and Z each represents hydrogen, R.sup.3 bonds to Y to represent a single bond, and W represents oxygen (DC107) is excluded.

Abstract: This invention relates to novel diastereomeric acid addition salts of homochiral hydroxylamines, to processes for obtaining such, to processes for the conversion thereof to the corresponding homochiral hydroxylamines, to certain novel homochiral hydroxylamines and the processes for using these as intermediates.

Abstract: The invention provides lanthanide chelates capable of intense luminescence. The celates comprise a lanthanide chelator covalently joined to a coumarin-like or quinolone-like sensitizer. Exemplary sensitzers include 2- or 4-quinolones, 2- or 4-coumarins, or derivatives thereof e.g. carbostyril 124 (7-amino-4-methyl-2-quinolone), coumarin 120 (7-amino-4-methyl-2-coumarin), coumarin 124 (7-amino-4-(trifluoromethyl)-2-coumarin), aminomethyltrimethylpsoralen, etc.The chelates form high affinity complexes with lanthanides, such as terbium or europium, through chelator groups, such as DTPA. The chelates may be coupled to a wide variety of compounds to create specific labels, probes, diagnostic and/or therapeutic reagents, etc. The chelates find particular use in resonance energy transfer between chelate-lanthanide complexes and another luminescent agent, often a fluorescent non-metal based resonance energy acceptor.

Abstract: The invention discloses side-chain homologous vitamin D derivatives of formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, B, and D have the meanings defined in the specification and either (1) A is a direct bond between carbon atoms 20 and 22 and X is an oxy alkylene radical, --(CH.sub.2).sub.n O-- where n is 1 to 3; (2) A is a methylene bridge, --CH.sub.2 --, between carbon atoms 20 and 22 and X is either an alkylene radical, --(CH.sub.2).sub.n -- or an oxy alkylene radical, --(CH.sub.2).sub.n O--, where n is 1 to 3; or (3) if A is a direct bond and B and D together form a second bond, then X(R.sup.5) (R.sup.6) is ##STR2## The compounds possess proliferation-inhibiting and cell-differentiating activity.

Abstract: A method for preparing a processable polyisothianaphthene polymer includes steps of dissolving an isothianaphthene monomer in a solvent and introducing therein an initiator to initiate a polymerization reaction to produce a precursor of poly(dihydroisothianaphthene), dissolving thoroughly the precursor of poly(dihydroisothianaphthene) in the solvent in an appropriate ratio to obtain a poly(dihydroisothianaphthene) solution, proceeding a dehydrogenation reaction for the poly(dihydroisothianaphthene) solution by introducing a dehydrogenation agent to obtain a polyisothianaphthene microgel solution, and terminating the dehydrogenation reaction by introducing an inhibitor. This invention offers a simple, feasible, and economical way to prepare a large-area film with uniform film thickness, excellent stability, and good electrochromic, conducting, and mechanical properties.

Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.

Abstract: The invention concerns benzenesulphonamide derivatives of the formula I ##STR1## wherein R.sup.1 is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl;R.sup.2 and R.sup.3 together form --A.sup.2 --X.sup.2 --A.sup.3 -- which defines a ring having 5 or 6 ring atoms, wherein A.sup.2 and A.sup.3 each is (1-3C)alkylene and X.sup.2 is oxy, thio, sulphinyl or sulphonyl;A.sup.1 is a direct link to X.sup.1 or is (1-3C)alkylene;X.sup.1 is oxy, thio or imino;Ar is optionally substituted phenylene;R.sup.4 is (1-4C)alkyl, fluoro-(2-4C)alkyl or optionally substituted phenyl or a heterocyclic moiety;R.sup.5 is hydrogen or (1-4C)alkyl; andR.sup.6 is hydrogen, halogeno, trifluoromethyl, (1-4C)alkyl or (1-4C)alkoxy;or a pharmaceutically-acceptable salt thereof;processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.

Abstract: An organic super-conductive material and a process for producing the same are disclosed, the material comprising a polymer having dispersed therein an organic super-conductive substance comprising an electron donor and an electron acceptor.

Abstract: In a process for preparing alkylene sulfides through the intramolecular dehydration reaction of mercaptoalkanols in a gaseous phase, catalysts are used, which are represented by the formula: M.sub.a X.sub.b Y.sub.c O.sub.d, where M represents at least one element selected from the group of alkali metals, alkaline earth metals and thallium; X represents at least one element selected from the group of Al, B, Si and P; Y represents at least one element selected from the group consisting of lanthanides, IIIA group, IVA group, VA group, IIIB group, IVB group, VB group and VIB group, excluding an element contained in M or X; O represents oxygen; and a and b are numerical values not equal to 0; b=0.2-100 and c=0-50 when a=1; and d is a numerical value determined according to a, b and c.

Abstract: Compounds of the Formula (5) and processes for their preparation and use, particularly in the manufacture of unsymmetrical triphenodioxazine dyes: ##STR1## wherein: Y is H, alkyl, substituted alkyl, alkoxy, Cl or Br;R is a group of Formula (3) ##STR2## R.sup.1 and R.sup.2 are each independently alkyl, or R.sup.1 and R.sup.2 together with the carbon atom to which they are attached form an optionally substituted 4, 5 or 6 membered alicyclic or heterocyclic ring;R.sup.3 is H;Z is Cl, Br or A--NH; andA is H or the residue of a primary amine.

Abstract: 1. A mesomorphic compound represented by the following formula 8 I]: ##STR1## wherein R.sub.1 and R.sub.2 respectively denote a straight chain or branch chain allyl group having 1-18 carbon atoms, wherein --CH.sub.2 -- in the alkyl group may be substituted by ##STR2## on condition that hetero atoms are not adjacent each other, R.sup.2 may be hydrogen atom, halogen atom, cyano group and trifluoromethyl group; n is 0 or 1, with the proviso that A.sup.1 denotes a single bond, ##STR3## when n is 0, A.sup.1 denotes a single bond when n is 1; A.sup.2 denotes any one of ##STR4## and X.sup.1, X.sup.2, Z.sup.1 and Z.sup.2 denote independently any one of hydrogen atom, halogen atom, cyano group and trifluoromethyl group, with proviso that X.sup.1, X.sup.2, Z.sup.1 and Z.sup.2 may not be all hydrogen atoms; Y denotes any one of ##STR5## a single bond.

Abstract: A mesomorphic compound represented by the following formula (I): ##STR1## wherein R.sup.1 and R.sup.2 respectively denote a linear or branched alkyl group having 3-18 carbon atoms capable of including one or more methylene groups which can be replaced with at least one species of ##STR2## with the proviso that --O-- cannot directly be connected to --O--, and R.sup.2 can also be halogen, --CN or --CF.sub.3 ; X denotes ##STR3## --CH.sub.2 O-- or --OCH.sub.2 ; A denotes ##STR4## and m and n are respecitvely 0 or 1 with the proviso that m+n=0 or 1. The mesomorphic compound is effective for providing a ferroelectric liquid crystal composition showing an improved low-temperature operation characteristic and a decreased temperature-dependence of response speed.

Abstract: A mesomorphic compound represented by the following formula (I): ##STR1## wherein R.sub.1 and R.sub.2 respectively denote a linear or branched alkyl group having 1-18 carbon atoms capable of having a substituent; X denotes any one of a single bond, --O--, ##STR2## Y denotes ##STR3## or --CH.sub.2 O--; and Z denotes any one of --O--, ##STR4## .

Abstract: A mesomorphic compound represented by the following formula (I): ##STR1## wherein R.sub.1 and R.sub.2 respectively denote a linear or branched alkyl group having 1-18 carbon atoms capable of having a substituent; X.sub.1 denotes any one of a single bond, --O--, ##STR2## X.sub.2 denotes any one of a single bond, --O--, ##STR3## Z.sub.1 denotes any one of ##STR4## --CH.sub.2 O-- and --CH.dbd.C(CN)--; and A.sub.1 denotes --A.sub.2 -- or --A.sub.2 --A.sub.3 -- wherein A.sub.2 and A.sub.

Abstract: Substituted amino derivatives represented by the formula: ##STR1## wherein R.sup.1 and R.sup.2 each stand for an acyclic hydrocarbon residue or an alicyclic hydrocarbon residue; R.sup.3 and R.sup.4 each stand for hydrogen or a hydrocarbon residue optionally containing hetero-atom(s); A stands for a carbon chain having two or more carbon atoms optionally containing ether linkage or sulfide linkage, which may be substituted and which may per se form a ring; X.sup.1 and X.sup.2 each stand for oxygen atom or sulfur atom; and Y stands for amino group or an organic residue bonded through nitrogen atom, which may form a ring by combining with a carbon atom constituting A; and their salts have anti-arrhythmic activity and are useful for prevention and treatment of a variety of arrhythmias.

Abstract: Described are the 6,7-(epithio)-3,7-dimethyl-1,3-octadienes having the structures ##STR1## and mixtures of same as well as the uses thereof in augmenting or enhancing the aroma or perfume compositions, colognes and perfumed articles including but not limited to solid or liquid anionic, cationic, nonionic or zwitterionic detergents, cosmetic powders, hair preparations and the like.

Abstract: A moisture curable composition contains:(a) one or more episulfide compounds having on the average more than one 1,2-epithiopropyl ether group of the formula I ##STR1## per molecule, and (b) one or more aliphatic N,N'-dialkyl-substituted diketimines of the general formula II ##STR2## wherein A is a divalent aliphatic, cycloaliphatic or arylaliphatic group, andR.sup.1 and R.sup.2 are each an alkyl group, or form together with the C-atom, to which they are bonded, a cycloalkyl group or cycloalkenyl group, and(c) at least one component, selected from the group of the setting accelerators as well as commercially available solvents, reactive diluents, plasticizers, thixotropic aids, fillers and pigments.This composition may be used as lacquers, paints and coatings for steel and concrete.There is also described a process for the preparation of 1,2-epithiopropyl ethers.

Abstract: Cyclic polycarbonate (or thiol analog) oligomer mixtures are prepared by the reaction of bishaloformates or their thio analogs, or mixtures thereof with dihydroxy or dimercapto compounds, with alkali metal hydroxides and various amines. The oligomer mixtures may be converted to polycarbonates or their thiol analogs by a method which is particularly adaptable to integration with polycarbonate processing operations. Polymerization may be conducted simultaneously with molding, extrusion and the like. The oligomer mixtures are adaptable to the preparation of filled prepregs.

Abstract: Alpha-L-Aspartyl-D-heteroaromatic-substituted glycine esters and amides are disclosed to be useful as high intensity sweeteners. These compounds can be used to sweeten a variety of foods, beverages and other oral products.

Abstract: Described is a process for preparing a mixture of t-mercapto terpenes defined according to the structure: ##STR1## and .alpha.-terpineol defined according to the structure: ##STR2## including the step of reacting the compound defined according to the structure: ##STR3## with an alkali metal thiocyanate defined according to the structure: ##STR4## wherein M represents alkali metal such as sodium, potassium or lithium in the presence of a phase transfer catalyst. The resulting product is then treated with lithium aluminum hydride followed by aqueous mineral acid to form a mixture of .alpha.-terpineol and the compound defined according to the structure: ##STR5## which mixture is useful for its organoleptic properties.

Abstract: A process for the preparation of aryl carboxylates is provided in which an arylmetallo carboxylate is contacted with an aryliodoso carboxylate in liquid medium to form the desired aryl carboxylate. Promoters can be employed to increase the rate of reaction and improve selectivity to the aryl carboxylate.

Abstract: A thermally stable, curable fluoroelastomer composition containing sulfonium curing agent is described. The composition is curable in reactive admixture with an inorganic acid acceptor and includes:(a) a fluoroelastomer comprising vinylidene fluoride;(b) at least one triorgano sulfonium compound; and(c) at least one aromatic polyhydroxy compound.

Abstract: A process for the preparation of alkylene episulfides or episelenides is provided which comprises contacting elemental sulfur or elemental selenium, respectively, with an olefin, preferably ethylene, while irradiating with electromagnetic radiation in the infrared to ultraviolet range. The alkylene episulfides and episelenides are useful in the production of a variety of functional polymers.

Abstract: Epithio compounds or mercaptans of the formula I ##STR1## wherein X is an oxygen or sulfur atom, --CH.sub.2 --, --CH(R.sub.1)--, --COO--, --NH-- or --NR.sub.1 --, each of Y and Z is hydrogen or together they are a direct bond, Q is hydrogen if Y and Z together are a direct bond, or is --OH, --SH, --OR.sub.1, --SR.sub.1, --OOCR.sub.1, --S--CH.sub.2).sub.n OH, --S--CH.sub.2).sub.n COOR.sub.1, --NHR.sub.1 or --N(R.sub.1).sub.2, n is an integer from 1 to 10, each of R and R.sub.1 independently is a cyclic or acyclic hydrocarbon radical of aliphatic or aromatic character containing 4 to 30 carbon atoms which can be interrupted by oxygen or sulfur, with the proviso that the groups R and R.sub.1 contain a total number of 8 to 30 carbon atoms. These compounds have excellent suitability for use as additives for lubricants, especially as extreme pressure and antiwear additives.

Abstract: Derivatives of 4,5-dihydro-4-oxofuran-2-carboxylic acid characterized by having two substituents at position 5 and in addition being optionally further substituted at position 3 with a lower alkyl group, as well as esters therefor are disclosed. The foregoing compounds are useful hypolipidemic agents in a mammal. Novel methods for the preparation of these compounds also are disclosed.